Research Supported by Biopharmaceutical Companies Boosts Montana Economy, Benefits Local Patients

WASHINGTON, D.C. (September 13, 2013) –  Working in collaboration with Montana clinicians and research institutions, America’s biopharmaceutical research companies have conducted more than 800 clinical trials of potential new medicines in Montana over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

PhRMA 2013 Industry Profile

Medicines in Development for Vaccines 2013

America’s biopharmaceutical companies are currently developing 271 vaccines to prevent – and in some cases treat – a variety of conditions, including infectious diseases, various forms of cancer and neurological disorders, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) 

Research & Hope Awards

Washington, D.C. (September 11, 2013) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the recipients of the 2013 Research & Hope Awards, honoring outstanding achievements in vaccines research and immunization by individuals and research teams in the biopharmaceutical sector, academic/public research and health care provider communities.

Medicines in Development: Vaccines

WASHINGTON, D.C. (September 11, 2013) – America’s biopharmaceutical companies are currently developing 271 vaccines to prevent – and in some cases treat – a variety of conditions, including infectious diseases, various forms of cancer and neurological disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

2013 Research and Hope Award bios

Linda Fu, MD, MScChildren’s National Medical Center Vaccine Program, under the guidance of Linda Yu-Sing Fu, MD, MSc

2013 Research and Hope Award bios

Douglas Lowy, MDDouglas Lowy, MD
Deputy Director
National Cancer Institute

2013 Research and Hope Award bios

Dr. Sophie BiernauxDr. Sophie Biernaux serves as Head of the Malaria Vaccine Franchise for GlaxoSmithKline Biologicals where she leads the company’s research and development efforts on malaria vaccines. Dr. Biernaux currently directs all aspects of GSK’s work in advancing the RTS,S malaria vaccine candidate, including the management of the Phase IIIs trial across Africa in conjunction with the company’s Global R&D Department.

Medicines in Development for Vaccines

PhRMA Vaccine Fact Book 2013

Pages

Subscribe to RSS - Innovation